Loading
In a Japanese trial the multi-kinase inhibitor lenvatinib shrank thymic carcinoma in about four in ten patients whose disease had progressed after platinum chemotherapy, leading to its approval in Japan.
Multicentre single-arm phase 2 trial of 42 patients with unresectable advanced or metastatic thymic carcinoma previously treated with platinum-based chemotherapy, given lenvatinib 24 mg daily.
The objective response rate was 38 percent and median progression-free survival 9.3 months. Hypertension and hand-foot syndrome were common and most patients needed dose reductions.
Lenvatinib is one of the few drugs with prospective evidence in thymic carcinoma after chemotherapy, alongside sunitinib and pembrolizumab.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/